Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $960.00, giving the company a market capitalization of 99.03B. It carries a P/E multiple of 21.03 and pays a dividend yield of 0.39%.
On 2026-11-18, Regeneron(REGN) stock moved within a range of $945.95 to $965.48. With shares now at $960.00, the stock is trading +1.5% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 933.26K, compared to an average daily volume of 1.05M.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
REGN News
...
CytomX Therapeutics (CTMX) announced it will receive a $5 million payment after reaching a preclinical milestone in its cancer drug development partnership with...
CytomX Therapeutics (CTMX) announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron (REGN), trigger...
Analyst ratings
67%
of 30 ratingsMore REGN News
Regeneron wins EU nod for alternative Libtayo regimen Nov 17, 2026, 2:17 PM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock By : Dulan Lokuwithana, SA News Edit...
Regeneron (REGN) announced that the European Commission, or EC, has approved an alternative, flexible dosing schedule for Libtayo across all approved skin, lung...
Barclays raised the firm’s price target on Regeneron (REGN) to $1,075 from $917 and keeps an Overweight rating on the shares. Published first on TheFly – the u...
has climbed strongly in recent years, and with the stock last closing at US$955.47 the obvious question is whether that price still lines up with what its earni...
Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Phase 2 PINNACLE trial results showing its investigational antibody baloncibart reduces abnormal standing...
Regeneron (REGN) announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome, or POTS, evaluating baloncibart, a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.